A new target for tumor therapy.
Jain
Rakesh K
RK
Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001808:Blood Vessels / Q000166:cytology; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000378:metabolism*; D042783:Endothelial Cells / Q000378:metabolism*; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D017874:Immediate-Early Proteins / Q000037:antagonists & inhibitors / Q000172:deficiency / Q000378:metabolism*; D051379:Mice; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D010100:Oxygen / Q000378:metabolism; D011393:Procollagen-Proline Dioxygenase; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D004268:DNA-Binding Proteins; D017874:Immediate-Early Proteins; D042461:Vascular Endothelial Growth Factor A; D011393:Procollagen-Proline Dioxygenase; C490189:Egln1 protein, mouse; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D010100:Oxygen